4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
Source: SeekingAlpha
2025-02-18 14:33:48 ET
Summary
- 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases.
- The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs.
- 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.
- Despite market skepticism about gene therapy, 4DMT's solid science, regulatory clarity, and financial stability make it a compelling investment opportunity.
...
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
4D Molecular Therapeutics Inc.
NASDAQ: FDMT
FDMT Trading
1.19% G/L:
$8.925 Last:
284,102 Volume:
$8.63 Open:
FDMT Latest News
March 18, 2026 04:05:00 pm
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
FDMT Stock Data
$519,643,507
47,993,463
N/A
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
